- Home
- CHCT vs STRO Comparison
CHCT vs STRO Comparison
Compare CHCT & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHCT | STRO |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | United States | United States |
| Employees | N/A | 133 |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 511.7M | 491.0M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | CHCT | STRO |
|---|---|---|
| Price | $18.33 | $30.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $18.00 | ★ $31.33 |
| AVG Volume (30 Days) | 143.4K | ★ 251.2K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 11.07% | N/A |
| EPS Growth | ★ 134.78 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $121,195,000.00 | N/A |
| Revenue This Year | $9.06 | N/A |
| Revenue Next Year | $8.61 | N/A |
| P/E Ratio | $256.57 | ★ N/A |
| Revenue Growth | ★ 4.67 | N/A |
| 52 Week Low | $13.23 | $0.67 |
| 52 Week High | $18.29 | $43.85 |
Technical Indicators
Market Signals| Indicator | CHCT | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 60.82 | 48.89 |
| Support Level | $16.45 | $23.53 |
| Resistance Level | $18.21 | $30.94 |
| Average True Range (ATR) | 0.36 | 2.65 |
| MACD | 0.04 | 0.39 |
| Stochastic Oscillator | 78.33 | 56.38 |
Price Performance
Historical ComparisonAbout CHCT Community Healthcare Trust Incorporated
Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems, or other healthcare service providers in non-urban markets. The company derives the majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.